Mend Amar Batbaatar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mend Amar Batbaatar has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Hirotaka Iwasaki
Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA
3 shared publications - Kiyoto Nishi
Shiga University of Medical Science, Japan
3 shared publications Narangerel Ganbaatar
3 shared publications- Shinya Ikeda
Department of Pharmacology, Seta Tsukinowa-cho, Otsu, Shiga, 520-2192, Japan
3 shared publications - Eiichiro Nishi
Department of Pharmacology, Shiga University of Medical Science, Otsu, Japan
2 shared publications Enkhjin Gansukh
2 shared publications
Latest Publications
- Open Access
- 2 September 2026
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 47
Nardilysin regulates Slc2a2 expression via an ISLET1-dependent enhancer mechanism in pancreatic β-cells
- 2 September 2026
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 47
Open AccessNardilysin regulates Slc2a2 expression via an ISLET1-dependent enhancer mechanism in pancreatic β-cells
- Open Access
- 5 March 2026
- Published by Elsevier in SSRN Electronic Journal
Nardilysin regulates Slc2a2 expression through ISLET1 recruitment to an evolutionarily conserved enhancer in pancreatic β-cells
GLUT2 (Slc2a2) is a key glucose transporter in pancreatic β-cells, and its reduced expression is closely linked to defective glucose-stimulated insulin secretion (GSIS) and diabetes. We previously reported that pancreatic β-cell–specific nardilysin (NRDC)-deficient mice (BetaKO) exhibit severe diabetic phenotype with defective GSIS and reduced Slc2a2 expression in islets. However, because BetaKO mice also showed reduced MafA, a key upstream regulator of Slc2a2, along with an increased α-cell/β-cell ratio and other secondary changes that could influence GLUT2 levels, the mechanism by which NRDC regulates Slc2a2 transcription remained unclear. Here, we demonstrate that NRDC controls Slc2a2 expression in a β-cell autonomous and MafA-independent manner. By integrating publicly available ATAC-seq and ChIP-seq datasets, we identified four active enhancer regions around the murine Slc2a2 locus, two of which are evolutionarily conserved in human islets. Luciferase assays revealed that NRDC selectively controls the activity of a conserved enhancer located 39k bp downstream of the Slc2a2 transcriptional start site. Chromatin immunoprecipitation (ChIP) and re-ChIP assays further revealed that NRDC binds to this enhancer and is required for efficient recruitment of ISLET1, a transcription factor upstream of Slc2a2. These findings indicate that NRDC directly regulates Slc2a2 in addition to MafA, highlighting multifaceted roles of NRDC in pancreatic β-cell gene regulation.
- 5 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessNardilysin regulates Slc2a2 expression through ISLET1 recruitment to an evolutionarily conserved enhancer in pancreatic β-cells
GLUT2 (Slc2a2) is a key glucose transporter in pancreatic β-cells, and its reduced expression is closely linked to defective glucose-stimulated insulin secretion (GSIS) and diabetes. We previously reported that pancreatic β-cell–specific nardilysin (NRDC)-deficient mice (BetaKO) exhibit severe diabetic phenotype with defective GSIS and reduced Slc2a2 expression in islets. However, because BetaKO mice also showed reduced MafA, a key upstream regulator of Slc2a2, along with an increased α-cell/β-cell ratio and other secondary changes that could influence GLUT2 levels, the mechanism by which NRDC regulates Slc2a2 transcription remained unclear. Here, we demonstrate that NRDC controls Slc2a2 expression in a β-cell autonomous and MafA-independent manner. By integrating publicly available ATAC-seq and ChIP-seq datasets, we identified four active enhancer regions around the murine Slc2a2 locus, two of which are evolutionarily conserved in human islets. Luciferase assays revealed that NRDC selectively controls the activity of a conserved enhancer located 39k bp downstream of the Slc2a2 transcriptional start site. Chromatin immunoprecipitation (ChIP) and re-ChIP assays further revealed that NRDC binds to this enhancer and is required for efficient recruitment of ISLET1, a transcription factor upstream of Slc2a2. These findings indicate that NRDC directly regulates Slc2a2 in addition to MafA, highlighting multifaceted roles of NRDC in pancreatic β-cell gene regulation.
- 16 April 2024
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 712-713, 149961
Nardilysin in vascular smooth muscle cells controls blood pressure via the regulation of calcium dynamics
- 16 April 2024
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 712-713, 149961
Nardilysin in vascular smooth muscle cells controls blood pressure via the regulation of calcium dynamics